• Emergent snaps up Adapt and its opioid overdose therapy for $735m pharmafile
    August 30, 2018
    Emergent BioSolutions has announced it has signed an agreement to acquire Adapt Pharma at a valuation of $735 million, a sum broken down into an up-front payment of $635 million and up to $100 million in milestone and royalty payments through to 2022.
PharmaSources Customer Service